As the mTOR inhibitor was administered after intrahepatic recurrence or detection of de novo gastric cancer in patient No.2 and No.3, it was difficult to infer the effect of mTOR inhibitors on tumor recurrence in these cases. The gene discussed is MTOR; the disease is gastric cancer.